Literature DB >> 16389204

A randomized controlled trial of interim methadone maintenance.

Robert P Schwartz1, David A Highfield, Jerome H Jaffe, Joseph V Brady, Carol B Butler, Charles O Rouse, Jason M Callaman, Kevin E O'Grady, Robert J Battjes.   

Abstract

CONTEXT: Effective alternatives to long waiting lists for entry into methadone hydrochloride maintenance treatment are needed to reduce the complications of continuing heroin dependence and to increase methadone treatment entry.
OBJECTIVE: To compare the effectiveness of interim methadone maintenance with that of the usual waiting list condition in facilitating methadone treatment entry and reducing heroin and cocaine use and criminal behavior.
DESIGN: Randomized, controlled, clinical trial using 2 conditions, with treatment assignment on a 3:2 basis to interim maintenance-waiting list control.
SETTING: A methadone treatment program in Baltimore. PARTICIPANTS: A total of 319 individuals meeting the criteria for current heroin dependence and methadone maintenance treatment.
INTERVENTIONS: Participants were randomly assigned to either interim methadone maintenance, consisting of an individually determined methadone dose and emergency counseling only for up to 120 days, or referral to community-based methadone treatment programs. MAIN OUTCOME MEASURES: Entry into comprehensive methadone maintenance therapy at 4 months from baseline; self-reported days of heroin use, cocaine use, and criminal behavior; and number of urine drug test results positive for heroin and cocaine at the follow-up interview conducted at time of entry into comprehensive methadone treatment (or at 4 months from baseline for participants who did not enter regular treatment).
RESULTS: Significantly more participants assigned to the interim methadone maintenance condition entered comprehensive methadone maintenance treatment by the 120th day from baseline (75.9%) than those assigned to the waiting list control condition (20.8%) (P<.001). Overall, in the past 30 days at follow-up, interim participants reported significantly fewer days of heroin use (P<.001), had a significant reduction in heroin-positive drug test results (P<.001), reported spending less money on drugs (P<.001), and received less illegal income (P<.02) than the waiting list participants.
CONCLUSION: Interim methadone maintenance results in a substantial increase in the likelihood of entry into comprehensive treatment, and is an effective means of reducing heroin use and criminal behavior among opioid-dependent individuals awaiting entry into a comprehensive methadone treatment program.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16389204     DOI: 10.1001/archpsyc.63.1.102

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  72 in total

1.  Treatment Outcomes of African American Buprenorphine Patients by Parole and Probation Status.

Authors:  Shannon Gwin Mitchell; Jan Gryczynski; Sharon M Kelly; Kevin E O'Grady; Jerome H Jaffe; Yngvild K Olsen; Robert P Schwartz
Journal:  J Drug Issues       Date:  2014-01

2.  Impact of interim methadone maintenance on HIV risk behaviors.

Authors:  Monique E Wilson; Robert P Schwartz; Kevin E O'Grady; Jerome H Jaffe
Journal:  J Urban Health       Date:  2010-07       Impact factor: 3.671

3.  Prospective effects of traumatic event re-exposure and post-traumatic stress disorder in syringe exchange participants.

Authors:  Jessica M Peirce; Robert K Brooner; Ken Kolodner; Rebecca L Schacht; Michael S Kidorf
Journal:  Addiction       Date:  2012-10-05       Impact factor: 6.526

4.  Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.

Authors:  Roger D Weiss; Jennifer Sharpe Potter; David A Fiellin; Marilyn Byrne; Hilary S Connery; William Dickinson; John Gardin; Margaret L Griffin; Marc N Gourevitch; Deborah L Haller; Albert L Hasson; Zhen Huang; Petra Jacobs; Andrzej S Kosinski; Robert Lindblad; Elinore F McCance-Katz; Scott E Provost; Jeffrey Selzer; Eugene C Somoza; Susan C Sonne; Walter Ling
Journal:  Arch Gen Psychiatry       Date:  2011-11-07

5.  Individual and system influences on waiting time for substance abuse treatment.

Authors:  Carey J A Carr; Jiangmin Xu; Cristina Redko; D Timothy Lane; Richard C Rapp; John Goris; Robert G Carlson
Journal:  J Subst Abuse Treat       Date:  2007-05-23

6.  Income level and drug related harm among people who use injection drugs in a Canadian setting.

Authors:  Cathy Long; Kora DeBeck; Cindy Feng; Julio Montaner; Evan Wood; Thomas Kerr
Journal:  Int J Drug Policy       Date:  2013-12-01

7.  Interim treatment: Bridging delays to opioid treatment access.

Authors:  Stacey C Sigmon
Journal:  Prev Med       Date:  2015-04-30       Impact factor: 4.018

8.  Social costs of robbery and the cost-effectiveness of substance abuse treatment.

Authors:  Anirban Basu; A David Paltiel; Harold A Pollack
Journal:  Health Econ       Date:  2008-08       Impact factor: 3.046

9.  Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial.

Authors:  Gail D'Onofrio; Patrick G O'Connor; Michael V Pantalon; Marek C Chawarski; Susan H Busch; Patricia H Owens; Steven L Bernstein; David A Fiellin
Journal:  JAMA       Date:  2015-04-28       Impact factor: 56.272

10.  Interim methadone treatment: impact on arrests.

Authors:  Robert P Schwartz; Jerome H Jaffe; Kevin E O'Grady; Timothy W Kinlock; Michael S Gordon; Sharon M Kelly; Monique E Wilson; Ashraf Ahmed
Journal:  Drug Alcohol Depend       Date:  2009-05-14       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.